- Home
- CEIX vs DYN Comparison
CEIX vs DYN Comparison
Compare CEIX & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEIX
- DYN
- Stock Information
- Founded
- CEIX 1864
- DYN 1984
- Country
- CEIX United States
- DYN United States
- Employees
- CEIX N/A
- DYN N/A
- Industry
- CEIX Coal Mining
- DYN Medicinal Chemicals and Botanical Products
- Sector
- CEIX Energy
- DYN Health Care
- Exchange
- CEIX Nasdaq
- DYN Nasdaq
- Market Cap
- CEIX 3.6B
- DYN 3.4B
- IPO Year
- CEIX 2017
- DYN 2020
- Fundamental
- Price
- CEIX $132.56
- DYN $29.73
- Analyst Decision
- CEIX Strong Buy
- DYN Strong Buy
- Analyst Count
- CEIX 2
- DYN 9
- Target Price
- CEIX $139.00
- DYN $52.44
- AVG Volume (30 Days)
- CEIX 592.8K
- DYN 1.1M
- Earning Date
- CEIX 11-05-2024
- DYN 11-12-2024
- Dividend Yield
- CEIX 0.19%
- DYN N/A
- EPS Growth
- CEIX N/A
- DYN N/A
- EPS
- CEIX 13.65
- DYN N/A
- Revenue
- CEIX $2,244,524,000.00
- DYN N/A
- Revenue This Year
- CEIX N/A
- DYN N/A
- Revenue Next Year
- CEIX $39.50
- DYN N/A
- P/E Ratio
- CEIX $9.71
- DYN N/A
- Revenue Growth
- CEIX N/A
- DYN N/A
- 52 Week Low
- CEIX $75.43
- DYN $10.12
- 52 Week High
- CEIX $132.65
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- CEIX 74.57
- DYN 46.53
- Support Level
- CEIX $124.08
- DYN $27.04
- Resistance Level
- CEIX $127.70
- DYN $35.68
- Average True Range (ATR)
- CEIX 4.39
- DYN 2.27
- MACD
- CEIX 0.37
- DYN 0.23
- Stochastic Oscillator
- CEIX 97.93
- DYN 31.13
About CEIX CONSOL Energy Inc.
CONSOL Energy Inc is a producer and exporter of high-BTU bituminous coal. It owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The principal activity involves mining, preparation, and marketing of thermal coal, sold to power generators. Its operating segment includes PAMC (Pennsylvania Mining Complex) and CONSOL Marine Terminal. The company generates maximum revenue from the PAMC segment.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.